Cadrenal Therapeutics, Book Value Per Share vs. Price To Book
| CVKD Stock | 11.20 0.40 3.45% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 8.86031516 | Current Value 9.3 | Quarterly Volatility 5.71386289 |
For Cadrenal Therapeutics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cadrenal Therapeutics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cadrenal Therapeutics, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cadrenal Therapeutics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cadrenal Therapeutics, Common over time as well as its relative position and ranking within its peers.
Cadrenal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cadrenal Therapeutics, Price To Book vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cadrenal Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Cadrenal Therapeutics, value to that of its competitors to determine the firm's financial worth. Cadrenal Therapeutics, Common is rated fifth in book value per share category among its peers. It is number one stock in price to book category among its peers fabricating about 1.82 of Price To Book per Book Value Per Share. At present, Cadrenal Therapeutics,'s Book Value Per Share is projected to increase based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cadrenal Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cadrenal Price To Book vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Cadrenal Therapeutics, |
| = | 3.09 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Cadrenal Therapeutics, |
| = | 5.64 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cadrenal Price To Book Comparison
Cadrenal Therapeutics, is currently under evaluation in price to book category among its peers.
Cadrenal Therapeutics, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cadrenal Therapeutics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cadrenal Therapeutics, will eventually generate negative long term returns. The profitability progress is the general direction of Cadrenal Therapeutics,'s change in net profit over the period of time. It can combine multiple indicators of Cadrenal Therapeutics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -7.6 M | -8 M | |
| Income Before Tax | -8.4 M | -8.8 M | |
| Total Other Income Expense Net | -724.2 K | -760.5 K | |
| Net Loss | -6.6 M | -6.9 M | |
| Net Loss | -8.4 M | -8.8 M | |
| Income Tax Expense | -165.9 K | -157.6 K | |
| Net Interest Income | 208.8 K | 185.6 K | |
| Interest Income | 224.2 K | 199.3 K | |
| Net Loss | -7.5 M | -7.9 M | |
| Change To Netincome | 4.7 M | 4.2 M | |
| Net Loss | (9.63) | (10.11) | |
| Income Quality | 0.42 | 0.24 |
Cadrenal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cadrenal Therapeutics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cadrenal Therapeutics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cadrenal Therapeutics,'s important profitability drivers and their relationship over time.
Use Cadrenal Therapeutics, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cadrenal Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Cadrenal Therapeutics, Pair Trading
Cadrenal Therapeutics, Common Pair Trading Analysis
The ability to find closely correlated positions to Cadrenal Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cadrenal Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cadrenal Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cadrenal Therapeutics, Common to buy it.
The correlation of Cadrenal Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cadrenal Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cadrenal Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cadrenal Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cadrenal Therapeutics, position
In addition to having Cadrenal Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
To fully project Cadrenal Therapeutics,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cadrenal Therapeutics, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cadrenal Therapeutics,'s income statement, its balance sheet, and the statement of cash flows.